Flow splitting to improve peak capacity in on-line LC×LC
The use of flow splitters between the two dimensions in on-line comprehensive two-dimensional liquid chromatography (LC×LC) has received little attention in comparison to their use in two dimensional gas chromatography.
The use of flow splitters between the two dimensions in on-line comprehensive two-dimensional liquid chromatography (LC×LC) has received little attention in comparison to their use in two dimensional gas chromatography.
In principle, the two dimensions should be optimized almost independently if the flow is split after the first dimension column and on‑line LC×LC is performed on this constant fraction of the first dimension effluent. When there is no flow splitting, any change in the first dimension flow-rate has an immediate impact on the second dimension. When there is a flow splitter there is the option to double the flow-rate into the first dimension column and do a 1:1 flow split without changing the sample loop size or the collection time. The sensitivity would be diminished but this can be partially compensated by using a larger injection. This would be a small price to pay for the increased resolving power and system flexibility. Other benefits include a 2-fold increase in the corrected 2D peak capacity and the number of observed peaks for a 15 min analysis time by using a post first dimension flow splitter. At a fixed analysis time the improvement results mainly from an increase in gradient time, which results from the reduced system re-equilibration time. To a lesser extent it is also due to the increased peak capacity achieved by full optimization of the first dimension.1
1. Marcelo Roberto Filgueira et al., Anal. Chem., doi: 10.1021/ac202317m
This story originally appeared in The Column. Click here to view that issue.
AI and GenAI Applications to Help Optimize Purification and Yield of Antibodies From Plasma
October 31st 2024Deriving antibodies from plasma products involves several steps, typically starting from the collection of plasma and ending with the purification of the desired antibodies. These are: plasma collection; plasma pooling; fractionation; antibody purification; concentration and formulation; quality control; and packaging and storage. This process results in a purified antibody product that can be used for therapeutic purposes, diagnostic tests, or research. Each step is critical to ensure the safety, efficacy, and quality of the final product. Applications of AI/GenAI in many of these steps can significantly help in the optimization of purification and yield of the desired antibodies. Some specific use-cases are: selecting and optimizing plasma units for optimized plasma pooling; GenAI solution for enterprise search on internal knowledge portal; analysing and optimizing production batch profitability, inventory, yields; monitoring production batch key performance indicators for outlier identification; monitoring production equipment to predict maintenance events; and reducing quality control laboratory testing turnaround time.
2024 EAS Awardees Showcase Innovative Research in Analytical Science
November 20th 2024Scientists from the Massachusetts Institute of Technology, the University of Washington, and other leading institutions took the stage at the Eastern Analytical Symposium to accept awards and share insights into their research.
